|
| Figure 1: Cell-based PCSK9-mediated LDL uptake inhibition function assay with recomninant D374Y-PCSK9 protein. A. Fluorescence labelled LDL uptake in human hepatocellular HepG2 cells (control, left panel) and the HepG2 cells treated with 13.4 nM D374Y-PCSK9 for 16 h (right panel). Bar, 20 μm. B. Effect of DMSO on the cell-based screening. HepG2 cells were incubated with the vehicle (PBS) and different dilutions of DMSO (0.5 μl or 1μl DMSO in 100 μλ medium) in D374Y-PCSK9 treated HepG2 cells. LDL uptake was quantified on the Fusion fluorescence plate reader. The average fluorescence reading ± SD are shown. (*P<0.05 vs. corresponding vesicle only, n=3 per group). C. Graphical comparison of the fluorescence readings from the samples of D374Y-PCSK9 treated and untreated. Each scatter plot represents relative fluorescence units (black round dot, D374Y-PCSK9 treated samples; black square, negative control) in different treatments. There was significant statistical significance (Student t-test, two tails, P<0.05) between the D374YPCSK9 treatment and control group. |
